Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells.

Synnott NC, Madden SF, Bykov VJN, Crown J, Wiman KG, Duffy MJ.

Transl Oncol. 2018 Dec;11(6):1343-1349. doi: 10.1016/j.tranon.2018.08.009. Epub 2018 Sep 6.

2.

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).

Coté D, Eustace A, Toomey S, Cremona M, Milewska M, Furney S, Carr A, Fay J, Kay E, Kennedy S, Crown J, Hennessy B, Madden S.

PLoS One. 2018 Aug 2;13(8):e0200996. doi: 10.1371/journal.pone.0200996. eCollection 2018.

3.

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.

Canonici A, Ivers L, Conlon NT, Pedersen K, Gaynor N, Browne BC, O'Brien NA, Gullo G, Collins DM, O'Donovan N, Crown J.

Invest New Drugs. 2018 Jul 30. doi: 10.1007/s10637-018-0649-y. [Epub ahead of print]

PMID:
30062574
4.

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.

Elster N, Toomey S, Fan Y, Cremona M, Morgan C, Weiner Gorzel K, Bhreathnach U, Milewska M, Murphy M, Madden S, Naidoo J, Fay J, Kay E, Carr A, Kennedy S, Furney S, Mezynski J, Breathhnach O, Morris P, Grogan L, Hill A, Kennedy S, Crown J, Gallagher W, Hennessy B, Eustace A.

Ther Adv Med Oncol. 2018 Jul 13;10:1758835918778297. doi: 10.1177/1758835918778297. eCollection 2018.

5.

Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.

Duffy MJ, McDermott EW, Crown J.

Tumour Biol. 2018 May;40(5):1010428318776169. doi: 10.1177/1010428318776169. Review.

PMID:
29775157
6.

Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.

Gullo G, Walsh N, Fennelly D, Bose R, Walshe J, Tryfonopoulos D, O'Mahony K, Hammond L, Silva N, McDonnell D, Ballot J, Quinn C, McDermott EW, Evoy D, Prichard R, Geraghty J, Amstrong J, Crown J.

Br J Cancer. 2018 Aug;119(3):374-380. doi: 10.1038/s41416-018-0114-x. Epub 2018 May 18.

PMID:
29773838
7.

Where youth matters-clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer.

Greally M, Kielty J, Watson GA, Das G, Malouf C, McSorley L, Coleman N, Quinn C, McDermott EW, Gullo G, Crown J, Prichard RS, Kelly CM, Walshe JM.

Ir J Med Sci. 2018 May 15. doi: 10.1007/s11845-018-1832-z. [Epub ahead of print]

PMID:
29766409
8.

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.

Duffy MJ, Synnott NC, Crown J.

Breast Cancer Res Treat. 2018 Jul;170(2):213-219. doi: 10.1007/s10549-018-4753-7. Epub 2018 Mar 21. Review.

PMID:
29564741
9.

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber RD, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):316-324. doi: 10.1016/j.ijrobp.2018.01.105. Epub 2018 Feb 6.

PMID:
29534902
10.

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Canonici A, Qadir Z, Conlon NT, Collins DM, O'Brien NA, Walsh N, Eustace AJ, O'Donovan N, Crown J.

Invest New Drugs. 2018 Aug;36(4):581-589. doi: 10.1007/s10637-017-0556-7. Epub 2018 Feb 2.

PMID:
29396630
11.

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles.

Martinez VG, O'Neill S, Salimu J, Breslin S, Clayton A, Crown J, O'Driscoll L.

Oncoimmunology. 2017 Aug 11;6(12):e1362530. doi: 10.1080/2162402X.2017.1362530. eCollection 2017.

12.

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Sonnenblick A, Salgado R, Brohée S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, De Azambuja E, Lieveke A, Piccart MJ, Bromberg JF, Sotiriou C.

Int J Oncol. 2018 Feb;52(2):424-432. doi: 10.3892/ijo.2017.4212. Epub 2017 Nov 27.

PMID:
29207087
13.

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J.

Ann Oncol. 2018 Apr 1;29(4):1056-1062. doi: 10.1093/annonc/mdx730.

PMID:
29145561
14.

Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?

Prior L, Lim M, Ward C, Featherstone H, Murray H, D'Arcy C, Crown J, Gullo G.

Cureus. 2017 Sep 5;9(9):e1654. doi: 10.7759/cureus.1654.

15.

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O'Donovan N, O'Connor D, Gallagher WM, Crown J, Fersht AR, Duffy MJ.

Cancer Lett. 2018 Feb 1;414:99-106. doi: 10.1016/j.canlet.2017.09.053. Epub 2017 Oct 22.

PMID:
29069577
16.

Mutant p53 as a target for cancer treatment.

Duffy MJ, Synnott NC, Crown J.

Eur J Cancer. 2017 Sep;83:258-265. doi: 10.1016/j.ejca.2017.06.023. Epub 2017 Jul 28. Review.

PMID:
28756138
17.

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.

Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.

18.

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.

Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O'Byrne KJ, O'Donovan N, Crown J.

Cell Immunol. 2017 Sep;319:35-42. doi: 10.1016/j.cellimm.2017.07.005. Epub 2017 Jul 15.

PMID:
28735814
19.

Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.

McDermott MSJ, Canonici A, Ivers L, Browne BC, Madden SF, O'Brien NA, Crown J, O'Donovan N.

Int J Oncol. 2017 Jun;50(6):2221-2228. doi: 10.3892/ijo.2017.3976. Epub 2017 Apr 26.

PMID:
28498399
20.

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.

PLoS One. 2017 May 11;12(5):e0177331. doi: 10.1371/journal.pone.0177331. eCollection 2017.

21.

Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.

Santra T, Roche S, Conlon N, O'Donovan N, Crown J, O'Connor R, Kolch W.

PLoS One. 2017 May 8;12(5):e0177058. doi: 10.1371/journal.pone.0177058. eCollection 2017.

22.

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ; tAnGo trial collaborators.

Lancet Oncol. 2017 Jun;18(6):755-769. doi: 10.1016/S1470-2045(17)30319-4. Epub 2017 May 4.

PMID:
28479233
23.

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

Li B, Ni Chonghaile T, Fan Y, Madden SF, Klinger R, O'Connor AE, Walsh L, O'Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn S, Jirstrom K, Caldas C, O'Connor DP, Gallagher WM.

Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28.

24.

Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.

Martinez VG, Crown J, Porter RK, O'Driscoll L.

Int J Cancer. 2017 Jun 15;140(12):2771-2784. doi: 10.1002/ijc.30705.

25.

Vitamin D analogues: Potential use in cancer treatment.

Duffy MJ, Murray A, Synnott NC, O'Donovan N, Crown J.

Crit Rev Oncol Hematol. 2017 Apr;112:190-197. doi: 10.1016/j.critrevonc.2017.02.015. Epub 2017 Feb 22. Review.

PMID:
28325259
26.

Vitamin D receptor as a target for breast cancer therapy.

Murray A, Madden SF, Synnott NC, Klinger R, O'Connor D, O'Donovan N, Gallagher W, Crown J, Duffy MJ.

Endocr Relat Cancer. 2017 Apr;24(4):181-195. doi: 10.1530/ERC-16-0463. Epub 2017 Feb 17.

PMID:
28213567
27.

CDK8: a new breast cancer target.

Crown J.

Oncotarget. 2017 Feb 28;8(9):14269-14270. doi: 10.18632/oncotarget.15354. No abstract available.

28.

Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy.

Duffy MJ, McDermott EW, Crown J.

Clin Chem. 2017 Apr;63(4):804-806. doi: 10.1373/clinchem.2016.267161. Epub 2017 Feb 10. No abstract available.

29.

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.

Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ.

Oncotarget. 2016 Nov 15;7(46):75518-75525. doi: 10.18632/oncotarget.12782.

30.

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J, Duffy MJ.

Int J Cancer. 2017 Jan 1;140(1):234-246. doi: 10.1002/ijc.30425. Epub 2016 Sep 24.

31.

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.

Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ.

J Clin Oncol. 2016 Oct 10;34(29):3518-3528. doi: 10.1200/JCO.2016.66.6693.

32.

Validated biomarkers: The key to precision treatment in patients with breast cancer.

Duffy MJ, O'Donovan N, McDermott E, Crown J.

Breast. 2016 Oct;29:192-201. doi: 10.1016/j.breast.2016.07.009. Epub 2016 Aug 9. Review.

PMID:
27521224
33.

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT.

J Natl Cancer Inst. 2016 Jul 4;108(8). pii: djw111. doi: 10.1093/jnci/djw111. Print 2016 Aug. No abstract available.

34.

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S, Kim ST, Huang X, Schnell P, Nadanaciva S, Bartlett CH, Slamon DJ.

Breast Cancer Res. 2016 Jun 28;18(1):67. doi: 10.1186/s13058-016-0721-5.

35.

The ADAMs family of proteases as targets for the treatment of cancer.

Mullooly M, McGowan PM, Crown J, Duffy MJ.

Cancer Biol Ther. 2016 Aug 2;17(8):870-80. doi: 10.1080/15384047.2016.1177684. Epub 2016 Apr 26. Review.

36.

Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up.

Murtagh G, Lyons T, O'Connell E, Ballot J, Geraghty L, Fennelly D, Gullo G, Ledwidge M, Crown J, Gallagher J, Watson C, McDonald KM, Walshe JM.

Breast Cancer Res Treat. 2016 Apr;156(3):501-506. doi: 10.1007/s10549-016-3781-4. Epub 2016 Apr 9.

PMID:
27060913
37.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

Mackey JR, Pieńkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press MF, Sauter G, Lindsay M, Houé V, Buyse M, Drevot P, Hitier S, Bensfia S, Eiermann W; Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 investigators.

Ann Oncol. 2016 Jun;27(6):1041-7. doi: 10.1093/annonc/mdw098. Epub 2016 Mar 2.

PMID:
26940688
38.

Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.

Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O'Donovan N, Crown J, Duffy MJ.

Endocr Relat Cancer. 2016 Apr;23(4):323-34. doi: 10.1530/ERC-16-0068. Epub 2016 Mar 1.

PMID:
26932782
39.

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.

Bell T, Crown JP, Lang I, Bhattacharyya H, Zanotti G, Randolph S, Kim S, Huang X, Huang Bartlett C, Finn RS, Slamon D.

Curr Med Res Opin. 2016 May;32(5):959-65. doi: 10.1185/03007995.2016.1157060. Epub 2016 Mar 2.

PMID:
26894413
40.

Transferrin-bound proteins as potential biomarkers for advanced breast cancer patients.

Dowling P, Palmerini V, Henry M, Meleady P, Lynch V, Ballot J, Gullo G, Crown J, Moriarty M, Clynes M.

BBA Clin. 2014 Sep 16;2:24-30. doi: 10.1016/j.bbacli.2014.08.004. eCollection 2014 Dec.

41.

Biomarkers in Breast Cancer: Where Are We and Where Are We Going?

Duffy MJ, Walsh S, McDermott EW, Crown J.

Adv Clin Chem. 2015;71:1-23. doi: 10.1016/bs.acc.2015.05.001. Epub 2015 Jun 23. Review.

PMID:
26411409
42.

ADAM10: a new player in breast cancer progression?

Mullooly M, McGowan PM, Kennedy SA, Madden SF, Crown J, O' Donovan N, Duffy MJ.

Br J Cancer. 2015 Sep 15;113(6):945-51. doi: 10.1038/bjc.2015.288. Epub 2015 Aug 18.

43.

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.

Mahgoub T, Eustace AJ, Collins DM, Walsh N, O'Donovan N, Crown J.

Int J Oncol. 2015 Sep;47(3):900-8. doi: 10.3892/ijo.2015.3097. Epub 2015 Jul 21.

44.

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J.

Eur J Cancer. 2015 Aug;51(12):1481-9. doi: 10.1016/j.ejca.2015.03.018. Epub 2015 Jun 11.

PMID:
26074397
45.

Healthy Cities Phase V evaluation: further synthesizing realism.

de Leeuw E, Green G, Tsouros A, Dyakova M, Farrington J, Faskunger J, Grant M, Ison E, Jackisch J, Lafond LJ, Lease H, Mackiewicz K, Östergren PO, Palmer N, Ritsatakis A, Simos J, Spanswick L, Webster P, Zamaro G, Crown J, Kickbusch I, Rasmussen N, Scally G, Biddle M, Earl S, Petersen C, Devlin J; World Health Organization European Healthy Cities Network.

Health Promot Int. 2015 Jun;30 Suppl 1:i118-i125. doi: 10.1093/heapro/dav047.

PMID:
26069313
46.

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.

Caiazza F, McGowan PM, Mullooly M, Murray A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J, Duffy MJ.

Br J Cancer. 2015 Jun 9;112(12):1895-903. doi: 10.1038/bjc.2015.163. Epub 2015 May 26.

47.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149.

PMID:
25746038
48.

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.

Stern HM, Gardner H, Burzykowski T, Elatre W, O'Brien C, Lackner MR, Pestano GA, Santiago A, Villalobos I, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Nuciforo P, Bee V, Mackey J, Slamon DJ, Press MF.

Clin Cancer Res. 2015 May 1;21(9):2065-74. doi: 10.1158/1078-0432.CCR-14-2993. Epub 2015 Feb 3.

49.

Predictive biomarkers for dasatinib treatment in melanoma.

Eustace AJ, Kennedy S, Larkin AM, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N.

Oncoscience. 2014 Mar 12;1(2):158-66. eCollection 2014.

50.

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.

Clemens MR, Gladkov OA, Gartner E, Vladimirov V, Crown J, Steinberg J, Jie F, Keating A.

Breast Cancer Res Treat. 2015 Jan;149(1):171-9. doi: 10.1007/s10549-014-3238-6. Epub 2014 Dec 30.

Supplemental Content

Support Center